CAHIC(SH:600195)2022-04-14 16:00Financial Performance - The company's operating revenue for 2021 was CNY 5,301,571,718.27, an increase of 6.06% compared to 2020[17]. - Net profit attributable to shareholders for 2021 was CNY 513,861,040.88, reflecting a year-on-year increase of 22.22%[17]. - The net cash flow from operating activities decreased by 42.50% to CNY 382,997,571.22 in 2021[17]. - Basic earnings per share for 2021 rose to CNY 0.5060, a 21.99% increase from the previous year[17]. - The company's total assets at the end of 2021 were CNY 7,436,605,421.28, up 9.92% from 2020[17]. - The weighted average return on equity increased to 10.84%, up 1.23 percentage points from 2020[17]. - The company's operating revenue for the reporting period was 5.302 billion RMB, with a net profit of 587 million RMB, and a net profit attributable to the parent company of 514 million RMB, resulting in a basic earnings per share of 0.5060 RMB[41]. - Total costs and expenses amounted to 4.795 billion RMB, representing 90.44% of the operating revenue[41]. Dividend Distribution - The company plans to distribute a cash dividend of 1.52 RMB per 10 shares, totaling 154,372,811.35 RMB based on the total share capital of 1,015,610,601 shares as of the end of 2021[4]. - The company implemented a cash dividend policy, distributing a total of 126,951,325.13 CNY in cash dividends, which is approximately 30.20% of the net profit attributable to shareholders for 2020[149]. Audit and Compliance - The company received a standard unqualified audit report from Zhongshun Yatai Accounting Firm, ensuring the authenticity and completeness of the financial report[4]. - There were no non-operating fund occupations by controlling shareholders or their related parties during the reporting period[4]. - The company has not violated decision-making procedures for providing guarantees to external parties[4]. - The company has established a comprehensive internal control system aimed at risk management and compliance, with no significant internal control deficiencies reported for the year 2021[153]. - The company maintained a standard unqualified opinion in its internal control audit report for the year 2021[154]. Market Position and Strategy - The company maintained a leading market share in government procurement for foot-and-mouth disease and avian influenza vaccines, ensuring stable market positioning[27]. - The company expanded its customer base significantly, with a focus on large clients in the feed sector, leading to major breakthroughs in customer development[28]. - The company is positioned as a key player in China's animal epidemic prevention system, actively participating in national disease control efforts[37]. - The company is adapting to regulatory changes, including the new veterinary GMP requirements, to enhance industry concentration and promote transformation and upgrading[42]. - The company is focused on reducing diarrhea rates in piglets through the development of antibiotic-free feed[75]. Research and Development - The company has implemented an innovative R&D mechanism, receiving over 100 research applications through its open research project fund, enhancing its R&D capabilities[37]. - The company's R&D investment amounted to 20,699.72 million RMB, representing 13.09% of operating revenue and 3.93% of net assets[84]. - Major R&D projects include the development of vaccines with investments of 396.72 million RMB for foot-and-mouth disease and 293.37 million RMB for porcine circovirus vaccines, showing a year-on-year increase of 87.89%[87]. - The company is actively engaged in the research and development of various new veterinary vaccines and diagnostic kits[75]. Environmental Responsibility - The company’s environmental protection facilities are fully operational, with all wastewater and emissions meeting regulatory standards[159]. - The total COD emissions from the subsidiary Zhongmu Anda were reported at 5.88 tons, with a concentration of 233.4 mg/L, well below the standard of 500 mg/L[155]. - The company has signed a wastewater treatment agreement with a treatment company to ensure compliance with the fermentation pharmaceutical industry wastewater discharge standards[159]. - The company has received multiple environmental impact assessment approvals for various projects, including a significant project approved in September 2021[163]. - The company has implemented a pollution prevention and control system, with all solid waste disposed of according to regulations[159]. Corporate Governance - The total pre-tax compensation for the board members and senior management amounted to 4,758,380 CNY[119]. - The company has established a remuneration and assessment committee to oversee the remuneration decisions for directors and senior management[127]. - The company’s board of directors and supervisory board remuneration is approved by the shareholders' meeting and determined based on national regulations and industry standards[127]. - The company has a strategic committee that includes members responsible for overseeing long-term strategic planning[136]. Investment and Expansion - The company plans to invest CNY 454.1 million in the construction of the Nanjing Biomedical Industrial Park project[131]. - A capital increase of CNY 250 million will be made to the wholly-owned subsidiary Inner Mongolia Zhongmu to enhance its profitability and core competitiveness[131]. - The company plans to enhance its market presence and enhance product offerings in response to increased demand in the pharmaceutical sector[46]. - The company is set to establish a wholly-owned subsidiary with an investment of CNY 100 million in Shandong Province[131]. Employee and Workforce Management - The company reported a total of 4,197 employees, with 2,011 in the parent company and 2,186 in major subsidiaries[142]. - The company has established a comprehensive training system covering all levels of employees to enhance professional skills and meet human resource needs[144]. - The company has a performance-based compensation policy aimed at maximizing the value of human resource investments[143]. - The company has a total of 343 employees with a master's degree or higher, indicating a strong educational background among its workforce[142].